Ruti Aga's Six-Year Ban: A Glucocorticoid, a Forged Prescription and the Arithmetic of Sanction

10 September: the date the statement used twice

The Athletics Integrity Unit released its statement on a Thursday. The item that took up the most space in it never happened on a track or a road — it happened on a prescription pad. On my Boston desk I drew the sanction sheet and three numbers came out: 2, 4, 6. Two years for presence, four for tampering, six in total. Two-thirds of the punishment attaches to something that was never found in a body. It was found on paper.

The date appears twice — 10 September, once as the start of the provisional suspension, once as the zero-point of the six-year count. Counting the ban from the provisional suspension is procedure, not leniency; time already served is credited. Ruti Aga is 32. In six years she will be 38. In Ethiopian women's marathoning, a 38-year-old with a doping record is not a selection decision; it is a formality. So the ban is six years and the career cost is larger than six years.

Which is why this case should be read as an audit, not a sermon. And the moment you start auditing, the first thing that breaks is not the drug. It is the drug's name.

What the file contains, and what it deliberately does not

Aga belongs to the Ethiopian road-racing layer that sits permanently in the top ten of major marathons but a step short of the world-record conversation. According to the AIU, she tested positive for methylprednisolone after winning a half marathon in China in March. A knee injury was cited. The prescription produced to justify the treatment was written by a family member who was not a registered medical practitioner; the clinic named on the document did not exist; and the clinic reportedly disowned the "old prescription pad from a former workplace" that was said to have been used.

Two things are blank in this file and I will record them as blank. First, the mark from that Chinese half marathon is not disclosed anywhere — no time, no splits, no field strength. Computing a gap to the world record from that would be dishonest; you cannot run arithmetic on an absent number. Second, neither the year of the March race nor the year the ban expires is stated. What is stated is the start: 10 September, plus six years.

For the career record I have to fall back on my own meet log, where Berlin 2026 records 2:18:34 for second place and Tokyo 2026 records 2:20:40 for the win, alongside three second-place finishes at World Marathon Majors. Those figures are not part of the AIU statement. Treat them as context, not evidence.

The first technical error: methylprednisolone is not a steroid

Media reports called methylprednisolone a "prohibited steroid" and said WADA classes it as performance-enhancing. That is imprecise in a way that changes the case. Methylprednisolone is a glucocorticoid — class S9 on the WADA Prohibited List. Anabolic steroids sit in class S1, and the two behave differently in law and in pharmacology.

The difference is not semantic. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injectable, oral or rectal routes. A therapeutic knee injection administered out-of-competition is entirely lawful. It becomes a violation when residues are present in an in-competition sample. The legal hinge of this entire case is therefore route and timing, not "steroid use."

Add the road-racing detail that only road-racing people carry: the in-competition window for a road race typically opens at 23:59 the day before the race. An injection given three or four days out, with an inadequate washout, produces a positive test after a race the athlete believed she had treated legally. The athlete may not know she is in breach. Her medical team is supposed to.

So the mislabel is not a slip. It points the reader toward a muscle-building conspiracy that the data does not support. The data supports something stranger: a substance with no proven endurance benefit produced a sanction heavier than many anabolic cases.

The TUE route that was open, and was closed by the athlete herself

Knee synovitis and intra-articular treatment are routine in high-volume marathoners. A properly supported athlete has two clean paths: obtain or apply for a Therapeutic Use Exemption, or observe the route-specific washout period so that the residue is gone before the window opens.

Neither path appears in this file. And that is where an individual lapse becomes something larger. If you need a forged prescription, it is because you did not have a real one. If you did not have a real one, you did not have the medical support a 2:18 athlete should have.

When the 2026 calendar collapsed and I built a no-meet window tracker from camp lists and TOPS funding dates across 14 javelin throwers, the lesson was the same one. Indian athletics' weak link was never talent; it was support architecture. Ethiopian road running is the same weakness in a different accent: enormous talent at the top, an empty medical-governance layer underneath. Training groups form around agents and coaches; document and exemption processes have nowhere to sit in that structure.

Three independent verification failures

The sanction sheet went up on the press-room board and half the room stopped talking. Not because of the length. Because the statement listed three separate failures of verification, each independent of the others.

One: the clinic on the prescription did not exist. Two: the prescriber was not a registered doctor; he was a family member. Three: the defence relied on an old prescription pad from a former workplace, and that clinic was willing to state on record that the pad was not theirs.

Three verification points, three failures. That is no longer a misunderstanding. It is a document that took effort to construct and no effort to defend. The AIU's four-year tampering sanction rests on this, and also on statements made in the investigative interview — the four years attach to the misleading account as much as to the paper. Language and translation conditions in AIU interviews with Ethiopian athletes have been a recurring friction point, and this case shows how quickly a technically under-supported athlete damages her own position in an interview room.

2 + 4 = 6: reading the panel's arithmetic

The arithmetic is worth reading because it encodes the reasoning. Under the Code, the standard sanction is four years, reducible for specified substances and for no-fault circumstances. Two years for presence tells us the panel accepted the substance as specified and did not find intent. Four years for tampering is the Code's standard tampering sanction. Six total.

The information is in what the sum excludes. With genuine medical records and a demonstrated route-and-timing explanation, the presence charge could have been argued at the no-fault or no-significant-fault end — a reprimand, or a much shorter period — and no tampering charge would have existed at all. Six years is the sanction that remained after the defence was destroyed.

One further signal: forged documentation is itself circumstantial evidence of concealment intent, yet it did not escalate the presence sanction. The panel weighed the two violations on separate scales, which is Code-consistent, and it means the forgery was treated as an offence in its own right rather than as an aggravating factor on the doping charge.

The career ledger: Tokyo 2026 and after

After the Tokyo 2026 finish line I opened the splits feed, not Twitter. Old habit — emotion arrives first, numbers second, and my job is to put numbers first. That race put Aga in the major-winner category, and it remains her largest asset. The violation is anchored to a later race; the statement does not announce a blanket annulment of prior results. Absent a finding of earlier use, the Tokyo title stays on the record.

Add three major runner-up finishes. That is a genuinely elite marathon career, not a two-year flare. I am marking it because the ban coverage usually deletes this part, and my profession's oldest disease is remembering athletes only by their last document.

Record and market are different things. Distance-running sponsorship is already thin; a doping record makes it thinner still. Commercially the case is closed. Competitively: a return at 38, after a six-year gap, in a country where a generation turns over every four years.

On the achievement side she is a 2026 major winner and a three-time major runner-up. On the opportunity side she is out of the 2028 Olympic cycle entirely. The drug did not decide that part. The drug would have cost two years. The pad cost the other four.

Ethiopia's depth: one name leaving changes nothing

Ethiopia's women's marathon has produced sub-2:14 performers, with a queue of 2:18–2:20 runners stacked beneath them. Losing one 32-year-old changes nothing in the selection calculus. That is not harshness; it is structure.

And the structure is the context. Where replacement is instant, an athlete has limited leverage to protect her own position — and the fear of losing a team slot converts directly into hiding injury. The knee is not decoration in this case. It is the cause.

That is the most useful part of the story. The drug was a symptom. The disease was an athlete with no economic option except to run through pain, and no lawful, documented route to treat that pain anywhere near her.

China's label circuit: appearance-fee economics colliding with testing economics

Between majors, Chinese and Gulf label races have become a lucrative, low-risk income tier for East African marathoners: decent appearance fees, shallow fields, modest competitive risk. That tier exists for runners in the 2:18–2:22 band — exactly Aga's stratum.

AIU testing density is rising fastest in the same tier. Two economies are now meeting in the same race, and the result is a new integrity exposure attached to results at this level — not only pharmacological, but documentary.

The pattern of East African road cases where an initial substance violation is compounded by a fabricated or altered explanation is growing. That does not make every athlete a forger. It means the enforcement frontier has moved from detection to document verification, and the athletes standing on that frontier have none of the infrastructure verification requires. One side has an investigation machine; the other has an entourage that cannot reach a registered physician.

The 2026 no-meet audit and the invisible thread

TrackLab India launched on a Tuesday; by Friday the cameras had opinions. When I started it in 2026, my only assets were Lalita Babar's 9:22.74 steeplechase in Rio 2026 and Neeraj Chopra's 86.48m world U20 record. The question was what happens to an athlete once the headlines leave.

In 2026 that question returned in another form. I pulled camp lists and TOPS funding dates for 14 javelin throwers and found the top group had gone 11 months without a sanctioned competition. The audit established something that applies directly here: an athlete's problem is usually not talent but the absence of a support system. Where medical support is informal, treatment is informal, and the next step after informal treatment is paperwork.

The AIU statement names only the family member. Whether an agent or manager was investigated is not disclosed. That is the missing link the next report should chase.

The inversion: six years measures entourage failure, not drug severity

The received wisdom is that the AIU is harsh on East African road runners and this case proves it. On the surface that reads fine — six years is not small. Push the logic one step and it flips.

In anabolic cases the athlete rarely has a lawful defence. In a glucocorticoid case, and specifically an in-competition-only class, the defence is widest: the injury is real, the treatment is standard, the route is legal, only the timing is wrong. This was the most defensible case an athlete could be handed. It could plausibly have closed at two years, or less. It closed at six.

The number therefore does not measure AIU rigour. It measures the absence of a defence machine. The size of the sanction is a proxy for the athlete's support deficit, not for the risk of the substance.

Second inversion: correlation is not causation. A forged prescription proves an attempt to conceal. It does not prove performance-enhancing misuse — and the panel agreed, since the presence sanction was not escalated. Calling the substance a "steroid" erases that distinction and inflates the case beyond its facts.

Third: the file is thin. No mark, no field quality, no year for the March race. Building large conclusions on a case that publishes so little is my profession's habit and its largest error. I will not claim the sanction is too long or too short. I will claim only that its shape was decided by a document, and the headline reversed that.

What to watch next

Watch one ratio in the next AIU quarterly report: tampering charges against presence charges. If the ratio climbs, enforcement has moved off chemistry and onto paperwork, and athletes are unprepared for that front.

Watch whether any major East African training camp declares a formal medical-support and TUE structure. The day that announcement lands, cases of this type halve.

Watch whether an integrity audit is created specifically for Chinese and Gulf label races. The appearance-fee economy and the testing economy are running in the same race, and nobody has yet written their joint ledger.

And the smallest question: if a CAS appeal trims even a year off the count that began on 10 September, the real question stays fixed — can a 2:18 athlete at 38 re-enter the same economy that pushed her toward a forged pad in the first place? Until that is answered, arguing about the length of the ban is wasted time.